Inhibrx Biosciences Inc (INBX) — Who's Buying and Selling (13F, Q2 2026)

INBX ranks #3440 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

INBX is a disclosed holding of Andreas Halvorsen (Viking Global Investors), one of the tracked superinvestors on AlphaSMO — it makes up 0.3% of that fund's own 13F portfolio.

INBX is a top-conviction position for Sanofi — at 20.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in INBX belongs to Morgan Stanley, but the position matters far more to Sanofi, who has 20.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Schonfeld Strategic Advisors LLC has added to its INBX position for two straight quarters, increasing it by $49.1M to reach $66.1M today.

Susquehanna International Group, LLP has trimmed its INBX position for two straight quarters, cutting it by $40.3M while still holding $9.7M.

INBX is up 2.1% today, and institutions have been net buyers of $248.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

INBX reported a net loss of $138.2M over the trailing twelve months.

• Not yet profitable — net loss of $138.2M over the trailing twelve months
• Revenue declined 7.1% year over year
• Net income improved year over year, from -$163.7M to -$138.2M
• Operating cash flow was negative, using $129.8M in cash
• Current ratio of 3.93x — enough short-term assets to cover short-term liabilities
• Liabilities run 17.33x equity — a highly leveraged balance sheet worth noting